Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):VED
ONLS
АТХ:R.03.C.C.05 Hexoprenaline
Pharmacodynamics:Competitively blocks oxytocin β2-adrenoceptors of the uterus and inhibits contractility of the myometrium. Has no effect on cardiac activity, blood flow of the pregnant and fetus. Increases the level of cAMP, activates adenylate cyclase, reducing the concentration of intracellular calcium.
The contractile activity of the myometrium decreases and stops within 10 minutes after the administration of the drug. The drug ensures the stability of the functional layer of the uterus within 12 hours (less than 4 cuts per hour).
Prevents and cures bronchospasm. With prolonged treatment, the pathologically elevated bronchial secretion decreases, the parameters of external respiration and gas composition of the blood improve.
Pharmacokinetics:After oral administration, up to 5-11% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 2 hours.
Therapeutic effect develops in 10 minutes after the reception. Metabolism in the liver.
The half-life is 50 minutes. Elimination with feces (up to 90%) and kidneys in the form of metabolites.
Indications:It is used in obstetrical practice for the purpose of tocolysis with the threat of abortion, for inhibition of birth pains - with the aim of immobilizing the uterus before obstetric or surgical intervention, stopping labor at the prehospital stage. For long-term treatment it is used for oral administration in case of the threat of premature birth, most often as a continuation of infusion therapy.
In pulmonology it is used to stop bronchospasm and prevent attacks of bronchial asthma.
XV.O60-O75.O60 Premature birth
XV.O60-O75.O62 Violations of labor [of the clan]
XV.O60-O75.O62.4 Hypertensive, uncoordinated and prolonged uterine contractions
XVI.P20-P29.P20 Intrauterine hypoxia
X.J40-J47.J44 Other chronic obstructive pulmonary disease
X.J40-J47.J45 Asthma
Contraindications:
Obstetric situations requiring immediate delivery: placental abruption, eclampsia, fetal hypoxia, dead fetus and so on. Cardiovascular diseases accompanied by tachyarrhythmias, thyrotoxicosis, ischemic heart disease, cardiomyopathy, heart defects, angle-closure glaucoma, severe liver and kidney disease, individual intolerance.
Carefully:
Diabetes mellitus, premature separation of amniotic fluid - the risk of developing chorioamnionitis.
Pregnancy and lactation:
Recommendations for FDA - Category B. Applicable in II-III trimester of pregnancy, is contraindicated in I trimester and lactation.
Dosing and Administration:Use in children
For the treatment of bronchospasm: from three years of age, 1 tablet (500 μg) 1-3 times a day, depending on the age.
Adults
Intravenously for tocolysis: 10 μg in 10 ml of 0.9% sodium chloride solution for 5-10 minutes, then drip intravenously at a rate of 0.3 μg per minute.
With prolonged use: intravenously drip - at 0,075 mkg per minute for 2 days, after which the interior of 0.5 mg every 3 hours, then every 4-6 hours.
For the treatment of bronchial obstructive syndrome: inside 1 tablet 3 times a day.
The highest daily dose: 400 mg.
The highest single dose: 500 mcg.
Side effects:Central and peripheral nervous system: anxiety, dizziness, tremor.
The cardiovascular system: hypotension, tachycardia, rarely - ventricular extrasystoles, transient cardialgia.
Digestive system: constipation due to decreased intestinal peristalsis, rarely - nausea, vomiting.
Dermatological reactions: Hyperhidrosis.
Reproductive system: atony of the uterus.
urinary system: decreased diuresis at the beginning of treatment.
Allergic reactions.
Overdose:Hypotension, tachycardia, tremor, headache, hyperhidrosis.
Treatment - dose reduction, the introduction of non-selective blockers of β-adrenergic receptors.
Interaction:Non-selective β-adrenoreceptor blockers weaken the action of hexoprenaline or completely neutralize it.
Methylxanthines (theophylline) potentiate the action of hexoprenaline.
Sympathomimetics increase the effect on cardiac activity.
Simultaneous use of certain funds for anesthesia (halothane) and sympathomimetics can lead to heart rhythm disturbances.
Antagonist of ergot preparations.
Special instructions:Before the beginning of treatment shows the intake of potassium preparations, restriction of table salt and liquid.